SCHEMBL3204767

SCHEMBL3204767

OCc1cc(-c2ccccc2)nn1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.55
TP53 P04637 2/20 0.52
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GLA P06280 1/20 0.50
HPGD P15428 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
PMP22 Q01453 1/20 0.49
HIF1A Q16665 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
LMNA P02545 3/20 0.48
HTT P42858 2/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3215777 0.84 PPARG (0.65) PPARGTP53ALDH1A1KDM4EGLA
SCHEMBL3219527 0.79 TP53 (0.54) PPARGTP53ALDH1A1KDM4EGLA
SCHEMBL3215524 0.79 PPARG (0.63) PPARGTP53ALDH1A1TSHRSMN1; SMN2
SCHEMBL3207494 0.77 PPARG (0.53) PPARGTP53ALDH1A1KDM4EGLA
SCHEMBL3215813 0.76 TP53 (0.52) PPARGTP53ALDH1A1KDM4EGLA
SCHEMBL3215823 0.76 TP53 (0.52) PPARGTP53ALDH1A1KDM4EGLA
SCHEMBL24892388 0.75 AKR1B1 (0.49) TP53CYP1A2CYP2C9SMN1; SMN2LMNA
SCHEMBL3198943 0.75 SMN1; SMN2 (0.72) PPARGTP53ALDH1A1KDM4ENPSR1
SCHEMBL8367181 0.74 MARS1 (0.65) PPARGTP53ALDH1A1KDM4EGLA
Hydrochloric Acid SCHEMBL8364783 0.73 MARS1 (0.64) PPARGTP53ALDH1A1KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PPARG 31/4885TP53 2684/4885ALDH1A1 212/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 PPARG 30/4885TP53 2792/4885ALDH1A1 118/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PPARG 31/4885TP53 2684/4885ALDH1A1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.